Stocksigma LogoStocksigma Logo

Curis Lifesciences Reports H1 FY'27 Results Following Key Strategic Acquisitions

Curis Lifesciences approved unaudited financial results for the half year ended 30th Sep'26. On a consolidated basis, revenue from operations reached

Curis Lifesciences Reports H1 FY'27 Results Following Key Strategic Acquisitions

Curis Lifesciences Ltd · Others (Uncategorized) · 16 Nov 2026, 4:54 pm

Curis Lifesciences Reports H1 FY'27 Results Following Key Strategic Acquisitions Curis Lifesciences approved unaudited financial results for the half year ended 30th Sep'26. On a consolidated basis, revenue from operations reached ₹3,703.39 lakh, with total income at ₹3,748.95 lakh and profit attributable to owners at ₹413.98 lakh (EPS: ₹5.76). Standalone revenue rose to ₹3,411.94 lakh from ₹2,790.89 lakh YoY, while standalone net profit stood at ₹413.50 lakh versus ₹421.09 lakh YoY. During the period, the company acquired a 51% stake in Uninova Lifesciences and a 49.95% stake in Nigeria-based Curosun Pharmaceutical.

Original exchange filing (PDF)

More announcements from Curis Lifesciences Ltd

All Curis Lifesciences Ltd announcements